Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.61 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.61 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | AMY2A | P04746 | 3/20 | 0.54 |
| ▸ | TYR | P14679 | 2/20 | 0.50 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GJA1 | P17302 | 1/20 | 0.49 |
| ▸ | GJB2 | P29033 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | IGF2R | P11717 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MGAM | O43451 | 2/20 | 0.47 |
| ▸ | SI | P14410 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cellobiose SCHEMBL21511124 | 1.00 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL24202679 | 1.00 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL23708014 | 1.00 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL21206262 | 1.00 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL23752618 | 1.00 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL24662526 | 1.00 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Maltotriose SCHEMBL23467170 | 1.00 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Maltotriose SCHEMBL24202675 | 1.00 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL25382543 | 1.00 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| Cellobiose SCHEMBL21114355 | 1.00 | LGALS8 (0.61) | LGALS8LGALS3LGALS4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026044162-A2 | PROCESS FOR MODIFYING GLUCO-OLIGOSACCHARIDES WITH AN ENRICHING STEP | CARGILL, INCORPORATED (US) | 2026-02-26 | — | — | WO | disclosed |
| WO-2026044164-A2 | PROCESS FOR MODIFYING GLUCO-OLIGOSACCHARIDES WITH KOJIBIOSE PHOSPHORYLASES | CARGILL, INCORPORATED (US) | 2026-02-26 | — | — | WO | disclosed |
| EP-4416298-B1 | PROCESS FOR MODIFYING GLUCO-OLIGOSACCHARIDES | CARGILL INC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4681555-A2 | PROCESS FOR MODIFYING GLUCO-OLIGOSACCHARIDES | Cargill, Incorporated (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250236898-A1 | PROCESS FOR MODIFYING GLUCO-OLIGOSACCHARIDES | CARGILL, INCORPORATED (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250136760-A1 | AMINO-ACID- AND AMINO-ALCOHOL-BASED POLYAMINE COMPOUNDS AND MEDICAL HYDROGELS FORMED THEREFROM | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| CN-119346874-B | Nano composite coating hard alloy cutter for intermetallic compound/superalloy processing and preparation method thereof | 成都欧珀琅精密工具有限公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025052117-A1 | BETA-GALACTOSIDASE ENZYME | OPTIBIOTIX LIMITED (GB) | 2025-03-13 | — | — | WO | disclosed |
| CN-119242977-B | High-performance nitrogen-containing hard alloy material based on vanadium-titanium-carbon nitride solid solution and preparation method thereof | 成都邦普切削刀具股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20250061975-A1 | SYSTEM AND METHOD FOR DETERMINING GLYCAN TOPOLOGY USING DE NOVO GLYCAN TOPOLOGY RECONSTRUCTION TECHNIQUES | UNIV BRANDEIS (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2021222660-A1 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING VIRAL INFECTIONS | KALEIDO BIOSCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-3877424-A2 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF | Kaleido Biosciences, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| CN-113260635-A | Oligosaccharide compositions and methods of use thereof | 卡莱多生物科技有限公司 | 2021-08-13 | — | — | CN | disclosed |
| US-20210198302-A1 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR REDUCING AMMONIA LEVELS | KALEIDO BIOSCIENCES, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| EP-3841127-A2 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR REDUCING AMMONIA LEVELS | Kaleido Biosciences, Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| CN-113056488-A | Oligosaccharide compositions and methods of use thereof for reducing ammonia levels | 卡莱多生物科技有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20210164926-A1 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| WO-2020227689-A1 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-10690651-B2 | Small molecule metabolites for the diagnosis of bacterial vaginosis and assessment of disease risk | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2020-06-23 | — | — | US | disclosed |
| WO-2020041531-A2 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR REDUCING AMMONIA LEVELS | KALEIDO BIOSCIENCES, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198302-A1 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR REDUCING AMMONIA LEVELS | OAT, OTC, FUCA2 | LGALS8 305/4885LGALS3 625/4885LGALS4 367/4885 |
| US-20250136760-A1 | AMINO-ACID- AND AMINO-ALCOHOL-BASED POLYAMINE COMPOUNDS AND MEDICAL HYDROGELS FORMED THEREFROM | CARM1, PNMT, ADM2 | LGALS8 1802/4885LGALS3 2711/4885LGALS4 3198/4885 |
| US-20210164926-A1 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF | OGT, FUT5, FUT6 | LGALS8 60/4885LGALS3 109/4885LGALS4 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.